[Distribution and drug resistance of pathogenic bacteria strains in nosocomial infection in Sun Yat-sen University Cancer Center from 2006 to 2007].
OBJECTIVE
Tumor patients have an increased risk of nosocomial infection due to hypoimmunity. Infection may affect antitumor therapies and even lead to death. This study aimed to investigate the susceptible factors, the distribution and drug resistance of the pathogens from tumor patients who suffered from nosocomial infection.


METHODS
Clinical records of 952 infected patients in Cancer Center of Sun Yat-sen University during 2006-2007 were reviewed. The infection rate, pathogen spectum and drug resistance of nosocomial infection were analyzed with EXCEL8.0 and SPSS10.0 software.


RESULTS
Among the 952 patients, pathogens were detected in 794 patients, with a rate of 83.4%. Of the 794 patients, 321 (40.4%) had gram-negative bacilli (GNB) infection (mainly caused by Escherichia coli), 265 (33.4%) had fungi infection (mainly caused by Candida albicans), and 208 (26.2%) had gram-positive cocci (GPC) infection (mainly caused by staphylococcus and streptococcus species). According to drug sensitivity and resistance test, GNB were sensitive to imipenem and amikacin, but strongly resistant to ampicillin with a rate of >90%; GPC were sensitive to vancomycin, but highly resistant against ampicillin; the fungi were sensitive to amphotericin B, voriconazole and flucytosine, but less sensitive to fluconazol.


CONCLUSIONS
GNB comprises the majority of pathogens separated from the hospitalized tumor patients in Cancer Center of Sun Yat-sen University from 2006 to 2007. Rational use of antibiotics based on drug sensitivity test could reduce fungi infection and drug resistance, therefore, help to prevent and control nosocomial infection effectively.
Sun
Yue-Li
YL
State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, China.
Zhao
Qing-Yu
QY
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy; D002176:Candida albicans / Q000302:isolation & purification; D002648:Child; D002675:Child, Preschool; D003428:Cross Infection / Q000188:drug therapy / Q000382:microbiology*; D024901:Drug Resistance, Multiple, Bacterial; D004926:Escherichia coli / Q000302:isolation & purification; D005260:Female; D006090:Gram-Negative Bacteria / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy; D009369:Neoplasms / Q000382:microbiology*; D012189:Retrospective Studies; D055815:Young Adult
D000900:Anti-Bacterial Agents